Literature DB >> 23015436

Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission.

Eun-Jin Bae1, He-Jin Lee, Edward Rockenstein, Dong-Hwan Ho, Eun-Bi Park, Na-Young Yang, Paula Desplats, Eliezer Masliah, Seung-Jae Lee.   

Abstract

Abnormal deposition and intercellular propagation of α-synuclein plays a central role in the pathogenesis of disorders such as Parkinson's Disease (PD) and dementia with Lewy bodies (DLB). Previous studies demonstrated that immunization against α-synuclein resulted in reduced α-synuclein accumulation and synaptic loss in a transgenic (tg) mouse model, highlighting the potential for immunotherapy. However, the mechanism by which immunization prevents synucleinopathy-associated deficits remains unknown. Here, we show that antibodies against α-synuclein specifically target and aid in clearance of extracellular α-synuclein proteins by microglia, thereby preventing their actions on neighboring cells. Antibody-assisted clearance occurs mainly in microglia through the Fcγ receptor, and not in neuronal cells or astrocytes. Stereotaxic administration of antibody into the brains of α-synuclein tg mice prevented neuron-to-astroglia transmission of α-synuclein and led to increased localization of α-synuclein and the antibody in microglia. Furthermore, passive immunization with α-synuclein antibody reduced neuronal and glial accumulation of α-synuclein and ameliorated neurodegeneration and behavioral deficits associated with α-synuclein overexpression. These findings provide an underlying mechanistic basis for immunotherapy for PD/DLB and suggest extracellular forms of α-synuclein as potential therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23015436      PMCID: PMC3752153          DOI: 10.1523/JNEUROSCI.1292-12.2012

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  70 in total

1.  Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice.

Authors:  Pritam Das; Victor Howard; Nicole Loosbrock; Dennis Dickson; M Paul Murphy; Todd E Golde
Journal:  J Neurosci       Date:  2003-09-17       Impact factor: 6.167

2.  Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein.

Authors:  He-Jin Lee; Ji-Eun Suk; Eun-Jin Bae; Jung-Ho Lee; Seung R Paik; Seung-Jae Lee
Journal:  Int J Biochem Cell Biol       Date:  2008-01-20       Impact factor: 5.085

3.  CSF tau and Abeta42: logical biomarkers for Alzheimer's disease?

Authors:  D Galasko
Journal:  Neurobiol Aging       Date:  1998 Mar-Apr       Impact factor: 4.673

4.  Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

Authors:  Eliezer Masliah; Edward Rockenstein; Anthony Adame; Michael Alford; Leslie Crews; Makoto Hashimoto; Peter Seubert; Michael Lee; Jason Goldstein; Tamie Chilcote; Dora Games; Dale Schenk
Journal:  Neuron       Date:  2005-06-16       Impact factor: 17.173

Review 5.  Recognition of immunoglobulins by Fcgamma receptors.

Authors:  Sergei Radaev; Peter Sun
Journal:  Mol Immunol       Date:  2002-05       Impact factor: 4.407

6.  Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma.

Authors:  Omar M A El-Agnaf; Sultan A Salem; Katerina E Paleologou; Leanne J Cooper; Nigel J Fullwood; Mark J Gibson; Martin D Curran; Jennifer A Court; David M A Mann; Shu-ichi Ikeda; Mark R Cookson; John Hardy; David Allsop
Journal:  FASEB J       Date:  2003-08-15       Impact factor: 5.191

7.  Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity.

Authors:  Diana L Price; Edward Rockenstein; Kiren Ubhi; Van Phung; Natalie MacLean-Lewis; David Askay; Anna Cartier; Brian Spencer; Christina Patrick; Paula Desplats; Mark H Ellisman; Eliezer Masliah
Journal:  PLoS One       Date:  2010-11-16       Impact factor: 3.240

8.  Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein.

Authors:  Wei Zhang; Shannon Dallas; Dan Zhang; Jian-Ping Guo; Hao Pang; Belinda Wilson; David S Miller; Biao Chen; Wanqin Zhang; Patrick L McGeer; Jau-Shyong Hong; Jing Zhang
Journal:  Glia       Date:  2007-08-15       Impact factor: 7.452

9.  Antibodies against alpha-synuclein reduce oligomerization in living cells.

Authors:  Thomas Näsström; Susana Gonçalves; Charlotte Sahlin; Eva Nordström; Valentina Screpanti Sundquist; Lars Lannfelt; Joakim Bergström; Tiago F Outeiro; Martin Ingelsson
Journal:  PLoS One       Date:  2011-10-31       Impact factor: 3.240

10.  alpha-Synuclein and neuronal cell death.

Authors:  Mark R Cookson
Journal:  Mol Neurodegener       Date:  2009-02-04       Impact factor: 14.195

View more
  155 in total

1.  Glucocerebrosidase depletion enhances cell-to-cell transmission of α-synuclein.

Authors:  Eun-Jin Bae; Na-Young Yang; Miyoung Song; Cheol Soon Lee; Jun Sung Lee; Byung Chul Jung; He-Jin Lee; Seokjoong Kim; Eliezer Masliah; Sergio Pablo Sardi; Seung-Jae Lee
Journal:  Nat Commun       Date:  2014-08-26       Impact factor: 14.919

Review 2.  Self-propagation of pathogenic protein aggregates in neurodegenerative diseases.

Authors:  Mathias Jucker; Lary C Walker
Journal:  Nature       Date:  2013-09-05       Impact factor: 49.962

3.  Pseudocatalytic Antiaggregation Activity of Antibodies: Immunoglobulins can Influence α-Synuclein Aggregation at Substoichiometric Concentrations.

Authors:  Leonid Breydo; Dave Morgan; Vladimir N Uversky
Journal:  Mol Neurobiol       Date:  2015-04-02       Impact factor: 5.590

Review 4.  α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies.

Authors:  Michael X Henderson; John Q Trojanowski; Virginia M-Y Lee
Journal:  Neurosci Lett       Date:  2019-06-03       Impact factor: 3.046

Review 5.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

Review 6.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

7.  Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.

Authors:  Markus Mandler; Elvira Valera; Edward Rockenstein; Harald Weninger; Christina Patrick; Anthony Adame; Radmila Santic; Stefanie Meindl; Benjamin Vigl; Oskar Smrzka; Achim Schneeberger; Frank Mattner; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2014-02-14       Impact factor: 17.088

8.  Autophagy modulates SNCA/α-synuclein release, thereby generating a hostile microenvironment.

Authors:  Anne-Maria Poehler; Wei Xiang; Philipp Spitzer; Verena Elisabeth Luise May; Holger Meixner; Edward Rockenstein; Oldriska Chutna; Tiago Fleming Outeiro; Juergen Winkler; Eliezer Masliah; Jochen Klucken
Journal:  Autophagy       Date:  2014       Impact factor: 16.016

Review 9.  Extracellular α--synuclein-a novel and crucial factor in Lewy body diseases.

Authors:  He-Jin Lee; Eun-Jin Bae; Seung-Jae Lee
Journal:  Nat Rev Neurol       Date:  2014-01-28       Impact factor: 42.937

Review 10.  Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.

Authors:  Elvira Valera; Brian Spencer; Eliezer Masliah
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.